SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients

Douglas Dieterich, a Tarik Asselah, b Dominique Guyader, c Thomas Berg, d Marcus Schuchmann, e Stefan Mauss, f Vlad Ratziu, g Peter Ferenci, h Dominique Larrey, i Andreas Maieron, jerry O. Stern, k Melek Ozan, l Yakov Datsenko, m Wulf Otto Böcher, m Gerhard Steinn

Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Service d'Hépatologie, AP-HP Hôpital Beaujon, INSERM UMR 1149, CRI, Université Paris Diderot, Clichy, France; Department of Liver Diseases, University of Rennes 1, Rennes, France; Sektion Hepatologie, Department für Innere Medizin, Neurologie und Dermatologie, Klinik für Gastroenterologie und Rheumatologie, Universitätshospital Leipzig AdR, Leipzig, Germany; Klinik für Innere Medizin, Klinikum Konstanz, Constance, Germany; Center for HIV and Hepatogastroenterology, Düsseldorf, Germany; Service d’Hépato-Gastroentérologie, Hôpital Privé-Salpétrière, Paris, France; Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria; Liver Unit-IRB-INSERM1040, Hôpital Saint Eloi, Montpellier, France; Department of Gastroenterology and Hepatology, Elisabethinen Hospital Linz, Linz, Austria; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

Faldaprevir is an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor which, when administered for 24 weeks in combination with pegylated interferon α-2a and ribavirin (PegIFN/RBV) in treatment-naive patients in a prior study (SILEN-C1; M. S. Sulkowski et al., Hepatology 57:2143–2154, 2013, doi:10.1002/hep.26276), achieved sustained virologic response (SVR) rates of 72 to 84%. The current randomized, open-label, parallel-group study compared the efficacy and safety of 12 versus 24 weeks of 120 mg faldaprevir administered once daily, combined with 24 or 48 weeks of PegIFN/RBV, in 160 treatment-naive HCV genotype 1 patients. Patients with maintained rapid virologic response (HCV RNA of <25 IU/ml at week 4 and undetectable at weeks 8 and 12) stopped all treatment at week 24, otherwise they continued PegIFN/RBV to week 48. SVR was achieved by 67% and 74% of patients in the 12-week and 24-week groups, respectively. Virologic response rates were lower in the 12-week group from weeks 2 to 12, during which both groups received identical treatment. SVR rates were similar in both groups for patients achieving undetectable HCV RNA. Most adverse events were mild or moderate, and 6% of patients in each treatment group discontinued treatment due to adverse events. Once-daily faldaprevir at 120 mg for 12 or 24 weeks with PegIFN/RBV resulted in high SVR rates, and the regimen was well tolerated. Differences in the overall SVR rates between the 12-week and 24-week groups were not statistically significant and possibly were due to IL28B genotype imbalances; IL28B genotype was not tested, as its significance was not known at the time of the study. These results supported phase 3 evaluation. (This study has been registered at ClinicalTrials.gov under registration no. NCT00984620).

Chronic hepatitis C virus (HCV) infection is a major health problem worldwide, with patients at risk of progressing to liver cirrhosis and hepatocellular carcinoma (1, 2). The NS3/4A protease inhibitors boceprevir and telaprevir were a major advance in the treatment of chronic HCV genotype 1 (GT-1) infection (3, 4). Addition of boceprevir or telaprevir to pegylated interferon α-2a (PegIFN) and ribavirin (RBV) increased sustained virologic response (SVR) rates compared to those of the placebo in HCV GT-1-infected patients (5–7) and enabled 40 to 60% of treatment-naive patients to reduce the treatment duration to 24 or 36 weeks rather than the 48 weeks required with PegIFN/RBV alone (3, 5). Shortening treatment duration is desirable in order to reduce the side effects associated with PegIFN and RBV.

However, boceprevir and telaprevir are associated with serious side effects, including rash and anemia, carry a high pill burden, require dosing every 8 h, and have numerous drug-drug interactions (3–7). Their use in clinical practice in patients with cirrhosis (8, 9) showed substantially higher mortality rates and an increased prevalence of severe side effects compared to clinical trials (5, 6, 10, 11). New direct-acting antivirals with improved tolerability, convenience, and drug-drug interaction profiles are needed (12).

Faldaprevir is an effective and highly specific noncovalently binding, linear HCV NS3/4A protease inhibitor with a pharmacokinetic profile conducive to once-daily (QD) dosing (13). In phase 1b studies, faldaprevir plus PegIFN/RBV induced profound antiviral responses in HCV GT-1 treatment-naive and treatment-experienced patients (13). The principal phase 2 program of faldaprevir consisted of the SILEN-C1 (in treatment-naive patients) and SILEN-C2 (in treatment-experienced patients) studies (NCT00774397). SILEN-C1, a large, double-blind, placebo-controlled study, showed that faldaprevir (120 or 240 mg QD for 24 weeks) plus PegIFN/RBV achieved higher SVR rates (72 to 84%) than PegIFN/RBV alone (56%) (14). SILEN-C3 (NCT00605098), initiated while SILEN-C1 and SILEN-C2 were still in progress, was added to the phase 2 program to address unanswered questions regarding optimal treatment duration with faldaprevir raised after the publication of data from other protease inhibitors (7, 15). The objective virologic endpoints of SILEN-C3 allowed the use of an
open-label and uncontrolled study design. The 120-mg dose of 
feldaprevir was selected for SILEN-C3 based on the results of a 
4-week study showing that the 120-mg and 240-mg faldaprevir 
doses had similar antiviral activity (13). At the time SILEN-C3 
was designed, a lead-in period, in which patients received PegIFN/ 
RBV alone for the first 3 days of therapy, was included in both 
treatment arms. This was based on the hypothesis that achieving 
sufficient plasma levels of PegIFN/RBV would avoid functional 
faldaprevir monotherapy and could minimize the early 
emergence of resistance mutations. Here, we report the results of 
the SILEN-C3 trial, comparing the efficacy and safety of 12 versus 24 
weeks of faldaprevir at 120 mg QD plus PegIFN/RBV in treat-
ment-na"eve HCV GT-1-infected patients. The study included pa-
tients with compensated liver cirrhosis.

MATERIALS AND METHODS

Patients. Eligible patients were aged 18 to 70 years, naive to interferon, 
PegIFN, and RBV, and had chronic HCV GT-1 infection (positive HCV 
erology for >6 months or liver histology typical of chronic hepatitis plus 
HCV RNA of $100,000 IU/ml at screening). Patients had a liver biopsy or 
Fibroscan within 2 years of screening to assess fibrosis or cirrhosis. A 
normal retinal fundoscopy within 6 months of study day 1 was required. 
Key exclusion criteria included liver disease resulting from causes other 
than chronic HCV, HCV of mixed genotype, hepatitis B virus infection, 
HIV infection, decompensated liver disease, or total bilirubin of $1.5$ 
the upper limit of normal (ULN).

Study design. Patients were recruited by specialists experienced in 
treating HCV and were screened and enrolled at 27 centers in Austria, 
Canada, France, Germany, Romania, and the United States. Patients were 
randomized 1:1 to faldaprevir at 120 mg QD for 12 or 24 weeks plus 
PegIFN/RBV for 24 or 48 weeks (Fig. 1). A dose of 120 mg was chosen for 
this study, because previous trials had shown it to have similar efficacy and 
better tolerability than a 240-mg dose (14). Patients who achieved a main-
tained rapid virologic response (mRVR; HCV RNA below the lower limit 
of quantification [LLOQ; $<25$ IU/ml] at week 4 and undetectable at weeks 
8 and 12) stopped all treatment at week 24; those who did not achieve mRVR continued PegIFN/RBV to week 48. 

The stopping rules were the following: HCV RNA load of $\geq 1,000$ 
IU/ml at two consecutive visits at least 2 weeks apart after previously 
undetectable HCV RNA, lack of early virologic response (absence of HCV 
RNA reduction by $\geq 2$ log$_{10}$ from baseline at week 12), or detectable HCV 
RNA at week 24.

Visits were scheduled for all patients for weeks $-4$ to $-1$ (screening), 
day 1, and for weeks 2, 4, 8, 12, 18, and 24. Patients who achieved mRVR 
stopped all treatment at week 24 and had follow-up visits at weeks 28, 36, 
and 48 (4, 12, and 24 weeks after the end of treatment [EOT]). Patients 
who did not achieve mRVR continued PegIFN/RBV through week 48 and 
had follow-up visits at weeks 60 and 72 (12 and 24 weeks after EOT). For 
patients who discontinued early, a follow-up visit was scheduled within 7 
days of the last dose of study drug.

All patients followed a rash management plan. The plan included def-
inations of the severity of treatment-emergent rash and other skin reac-
tions, the use of sunscreen by all patients, and protocols for management 
of skin reactions (including immediate discontinuation of all study med-
ications in the event of severe rash).

The randomization list was generated by a pseudo-random number 
generator, with a third-party interactive voice response system (IVRS) to 
assign randomization numbers. All patients provided written informed 
consent, and the study was conducted in accordance with the principles of 
the Declaration of Helsinki, followed the International Conference on 
Harmonised Tripartite Guideline for Good Clinical Practice, and was reg-
istered at www.clinicaltrials.gov (NCT00984620). Study materials were 
approved by independent ethics committees or institutional review 
boards of participating centers and by the relevant authorities in each 
country.

Study endpoints. The primary endpoint was virologic response (HCV 
RNA undetected) at week 28 (termed the week 28 virologic response, 
W28VR) and was selected to inform the phase 3 dose regimen selection. 
Key secondary endpoints included SVR (HCV RNA undetectable) 24 
weeks after completion of all therapy, rapid virologic response (RVR; 
HCV RNA undetectable at week 4), time to reach undetectable HCV RNA 
levels in plasma, safety, and tolerability. Patients without data 24 weeks 
after the end of therapy were recorded as SVR failures.

Efficacy assessments. Plasma HCV RNA levels were measured using 
the COBAS TaqMan HCV/HPS assay (Roche Molecular Diagnostics) at a 
central laboratory (Covance Central Laboratory Services). The LLOQ was 
25 IU/ml. Viral genotyping included population sequencing of the NS3/ 
NS4A region. Genotyping was performed for all patients at baseline, 
for patients who discontinued study treatment, and on samples from patients 
whose HCV RNA levels reached a plateau above the LLOQ or rebounded 
during the study period.

Safety assessments. All adverse events (AEs), including time of onset, 
et end time, intensity, intervention, and outcome, were reported in writing 
by the investigator to the sponsor based on a patient’s toleration of the 
treatment as mild (easy to tolerate), moderate (interference with usual activity), 
severe (incapacitating or preventing work or usual activities). Rash
was graded by the investigator as mild (localized), moderate (diffuse, 30 to 70% body surface area), or severe (diffuse, generalized, mucous membranes involved, organ dysfunction, signs of anaphylaxis, or life threatening). Vital signs, electrocardiogram, and routine laboratory parameters were evaluated. Growth factors (e.g., erythropoiesis-stimulating agents and granulocyte colony-stimulating factor) were permitted at the investigator’s discretion in the event of anemia or neutropenia.

Statistical assessments. The sample size was adopted from the SILEN-C1 trial (14) and was calculated from the expected response rates and the effect of sample size on the likelihood of false-positive or false-negative results. This showed that 70 patients in each treatment arm would be appropriate. No formal statistical testing was planned, and no hypotheses were defined. Descriptive statistics for efficacy and safety were presented. For efficacy endpoints, to provide a quantitative assessment of the magnitude of differences in efficacy between the two durations, 95% confidence intervals (CI) along with corresponding 2-sided P values were calculated using Cochran-Mantel-Haenszel methods adjusted for GT-1 subtype (1a or 1b). However, since the study was not designed or powered to allow any formal testing of differences between the two durations, these should be interpreted only descriptively without inference being made to a larger population of patients.

RESULTS

Patient disposition and baseline characteristics. Between September and October 2009, 208 patients were enrolled, and 160 entered into the trial; 81 were randomized to the 12-week group and 79 to the 24-week group (Fig. 2). All randomized patients received at least one dose of study drug. One patient in the 24-week group discontinued faldaprevir on day 82 and PegIFN/RBV on day 85 and then was lost to follow-up. This was deemed to be a major protocol violation, and the patient was excluded from efficacy analysis according to the protocol. Premature discontinuation for any reason occurred in 7% (6/81) of patients in the 12-week group and 15% (12/79) in the 24-week group during the treatment phase; five patients (6%) in each group discontinued because of AEs. Of the five patients in the 12-week group, one discontinued faldaprevir and PegIFN/RBV due to the diagnosis of severe bone pain during PR lead-in and discontinued before receiving FDV; b, includes lack of efficacy and lost to follow-up. QD, once daily; PR, pegylated interferon α-2a and ribavirin; mRVR, maintained rapid virologic response (HCV RNA below the lower limit of quantification [LLOQ; <25 IU/ml] at week 4 and undetectable at weeks 8 and 12).

FIG 2 Patient disposition. Footnotes: a, one patient experienced severe bone pain during PR lead-in and discontinued before receiving FDV; b, includes lack of efficacy and lost to follow-up. QD, once daily; PR, pegylated interferon α-2a and ribavirin; mRVR, maintained rapid virologic response (HCV RNA below the lower limit of quantification [LLOQ; <25 IU/ml] at week 4 and undetectable at weeks 8 and 12).
prostate cancer during screening. Another discontinued PegIFN/RBV during lead-in due to an AE (bone pain) and did not receive faldaprevir.

Ethnicity, body mass index, and presence of liver cirrhosis were evenly balanced in the treatment groups, but the 12-week group was older and had more patients with HCV RNA of $\geq 800,000$ IU/ml and GT-1a infection (Table 1). IL28B testing was not performed in this study, since its predictive effect on response to IFN-based treatment had not yet been established when the study was initiated.

**Efficacy.** The SVR rate was 67% (54/81) in the 12-week group and 74% (58/78) in the 24-week group (adjusted difference, 4.78%; 95% CI, 9.0, 18.6; $P = 0.51$) (Table 2). Of the 10 patients in each treatment group with compensated liver cirrhosis at baseline, 3 patients in the 12-week group and 4 in the 24-week group achieved SVR. RVR was achieved by 59% (48/81) and 72% (56/78) of patients in the 12-week and 24-week groups, respectively (adjusted difference, 9.02%; 95% CI, 14.3, 11.8; $P = 0.23$). The primary endpoint (W28VR) was met by 75% (61/81) and 77% (60/78) of patients in the 12- and 24-week groups, respectively (adjusted difference, $-1.25$%; 95% CI, $-5.3$, 23.3; $P = 0.86$). In each treatment group, 60% (61/100) of patients with compensated liver cirrhosis at baseline achieved W28VR. The criterion for shortened overall treatment duration, mRVR, was achieved by 70% (57/81) and 83% (65/78) of patients in the 12- and 24-week groups, respectively (adjusted difference, 10.36%; 95% CI, $-1.9$, 22.6; $P = 0.12$); these patients stopped all treatment at week 24 (Fig. 3A). Their SVR rates were 88% (50/57) and 86% (56/65), respectively. Patients without mRVR were assigned by protocol to receive 48 weeks of treatment and had SVR rates of $<20\%$ (Fig. 3B). Shorter time to achieve undetectable HCV RNA was associated with higher likelihood of SVR; 95% (40/42) of patients with HCV RNA undetectable by week 2 achieved SVR (Fig. 4).

Virologic breakthrough occurred in 12% (10/81) and 9% (7/78) of patients in the 12- and 24-week groups, respectively (Table 3). Rates of relapse were similar across the two groups. Across both groups, approximately 2% of patients with undetectable levels of HCV RNA at week 2 relapsed. More patients achieved undetectable levels of HCV RNA up to week 12 in the 24-week group than in the 12-week group (Fig. 5).

The predominant emergent NS3/4A resistance-associated variants (RAVs) were R155K in 79% (15/19) of GT-1a virologic failures and D168V in 59% (10/17) of GT-1b virologic failures. All breakthroughs during faldaprevir/PegIFN/RBV treatment were associated with one of these RAVs, except one GT-1g R155K variant. Virologic breakthrough during PegIFN/RBV treatment occurred in five patients (Table 3): in four cases, this was associated with R155K GT-1a; no known RAVs were detectable in the other GT-1a case. Rarer NS3/4A RAVs detected during relapse included one each of R155S (GT-1a), D168E (GT-1a), and D168E (GT-1b).

**Safety.** The median faldaprevir treatment duration was 81 days for the 12-week group and 165 days for the 24-week group, with 93% (75/81) and 85% (67/79) of the 12- and 24-week groups, respectively, completing scheduled faldaprevir treatment. Median treatment duration for all HCV medication was 168 days for both treatment groups.

The open-label design of the study limits interpretation of the safety data. Most AEs were mild to moderate and were considered related to at least one of the study drugs. Six serious AEs occurred during the faldaprevir treatment phase, in three patients in each treatment group. Three serious AEs were considered related to treatment (anemia, neutropenia, and erythema); all resolved following treatment discontinuation, dose reduction, or without treatment modification. There were no deaths during the study. The most common AEs were gastrointestinal and were mostly mild. Most gastrointestinal AEs started during the first 8 weeks of treatment. In the 24-week group, one patient reported a severe rash (morbilliform). A second patient reported moderate rash during faldaprevir treatment, leading to discontinuation of all therapy. One patient in the 24-week group had a mild photosen-
ment laboratory abnormalities in the two faldaprevir treatment
treatment.

June 2014 Volume 58 Number 6 aac.asm.org

Severe anemia achieved SVR.

The faldaprevir 24-week treatment phase. All three patients with

8.5 g/dl). Hemolytic anemia was reported in one patient during

/ H11021

patient in each group experienced severe anemia (hemoglobin,

cluded six (8%) and seven (9%) patients, respectively, during

and seven (9%) in the 24-week group reported severe AEs; these

reported during the faldaprevir phase are summarized in Table 4.

Sensitivity reaction during faldaprevir/PegIFN/RBV treatment. AEs

reported during the faldaprevir phase are summarized in Table 4.

Overall, 10 patients (12%) in the faldaprevir 12-week group

and seven (9%) in the 24-week group reported severe AEs; these

included six (8%) and seven (9%) patients, respectively, during

faldaprevir therapy. Except for three cases (headache, hypothy-

roidism, and ulcerative colitis), all of the severe AEs resolved. One

patient in each group experienced severe anemia (hemoglobin,

<8.5 g/dl). Hemolytic anemia was reported in one patient during

the faldaprevir 24-week treatment phase. All three patients with

severe anemia achieved SVR.

Table 5 shows the incidence of marked laboratory changes on
treatment. Similar proportions of patients experienced on-treat-
ment laboratory abnormalities in the two faldaprevir treatment

groups. Increases in total bilirubin levels, mostly owing to an in-
crease in unconjugated bilirubin, were observed during faldapre-
vir treatment. Generally, aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) levels decreased from baseline
during faldaprevir treatment. At study end, median laboratory
values for hematologic parameters, bilirubin, and liver enzymes
were within the reference ranges in both groups. Overall, four
patients had a conjugated/total bilirubin ratio of >0.5 at any time
during the trial. None of these patients had AST or ALT elevations
greater than 3 × ULN, none reported jaundice, and all returned to
a ratio of ≤0.5 by study end. All four of these patients completed
all treatments.

**DISCUSSION**

The SILEN-C3 trial results show that a 12-week treatment dura-
tion of faldaprevir at 120 mg QD on a background of PegIFN/RBV
achieves efficacy similar to that of 24 weeks of faldaprevir therapy
for treatment-naive patients infected with HCV GT-1. High SVR
rates of ≥67% and W28VR rates of ≥75% were obtained in a
population which included approximately 12% of patients with
liver cirrhosis.

The majority of patients (70% and 83% in the 12- and 24-week
groups, respectively) met the response criterion (mRVR) for
shortened PegIFN/RBV treatment and were eligible for 24 weeks
of therapy. The mRVR rates were higher than the RVR rates, be-
cause RVR was defined as undetectable levels of HCV RNA at
week 4, whereas mRVR included HCV RNA levels below the
LLOQ at this time.

Despite receiving the same regimen until week 12, the 24-week
group achieved higher rates of undetectable HCV RNA from week
2 onwards and had fewer patients who never achieved undetect-
able viral load compared to the 12-week group. Historically, for
PegIFN/RBV-treated GT-1 patients, RVR at week 4 has been pre-
dictive of achieving SVR (17), and patients requiring a longer time
to eliminate the virus from plasma may benefit from longer treat-
ment. Previous studies of faldaprevir alone and combined with
PegIFN/RBV (13) suggest that a reliable time point of SVR pre-
diction is week 2 or earlier. In this study, SVR rates were similar
for the 12- and 24-week groups in patients achieving undetectable
levels of HCV RNA independent of the time to first negative HCV
groups were low and consistent with those observed for the same rates of 79% in treatment-naive patients (20).

Virat 120 mg QD plus PegIFN/RBV without lead-in achieves SVR in phase 3 clinical trials whose results indicate that faldaprevir was more efficacious than lead-in regimens employing otherwise identical doses and durations (14,19), although the reasons for these differences are unknown. Lead-in has not been incorporated into any phase 3 trial design for faldaprevir. This trial demonstrated the faldaprevir dose in SILEN-C1 (14). The predominance of the major NS3/4A resistance variant R155K in GT-1a and D168V in GT-1b has been observed in earlier studies, and these variants reduce the activity of faldaprevir in vitro (21); this resistance profile overlaps with that of other protease inhibitors (22).

The types and frequencies of AEs were similar in the 12- and 24-week groups. As shown in Table 4, the most common AE was nausea, which occurred in 17% (22%) of patients in the 12-week (24-week) group. Other common AEs included skin disorders (pruritus, dry skin, rash) and gastrointestinal disorders (nausea, vomiting).

RNA result. This indicates that the lower response rates in the 12-week group compared with the 24-week group were due to an imbalance in baseline factors, including age, viral load of ≥800,000 IU/ml, and the proportion of patients who had HCV GT-1a. The small sample sizes and the absence of data on other host factors that predict the response to treatment, such as IL28B gene polymorphisms (18), precluded statistical analyses of factors determining the response.

A 3-day PegIFN/RBV lead-in period was included before the first dose of faldaprevir, reflecting mainstream treatment strategies at the time of trial onset. Following the commencement of this study, the phase 2 SILEN-C1 and -C2 studies reported that a strategy with no lead-in achieved SVR rates approximately 10% higher than those of lead-in regimens employing otherwise identical doses and durations (14,19), although the reasons for these differences are unknown. Lead-in has not been incorporated into any phase 3 trial design for faldaprevir. This trial demonstrated the efficacy of the 120-mg dose of faldaprevir which has been used to inform phase 3 clinical trials whose results indicate that faldaprevir at 120 mg QD plus PegIFN/RBV without lead-in achieves SVR rates of 79% in treatment-naive patients (20).

Relapse and breakthrough rates for the 12- and 24-week groups were low and consistent with those observed for the same faldaprevir dose in SILEN-C1 (14). The predominance of the major NS3/4A resistance variant R155K in GT-1a and D168V in GT-1b has been observed in earlier studies, and these variants reduce the activity of faldaprevir in vitro (21); this resistance profile overlaps with that of other protease inhibitors (22).

The types and frequencies of AEs were similar in the 12- and 24-week groups. As shown in Table 4, the most common AE was nausea, which occurred in 17% (22%) of patients in the 12-week (24-week) group. Other common AEs included skin disorders (pruritus, dry skin, rash) and gastrointestinal disorders (nausea, vomiting).

RNA result. This indicates that the lower response rates in the 12-week group compared with the 24-week group were due to an imbalance in baseline factors, including age, viral load of ≥800,000 IU/ml, and the proportion of patients who had HCV GT-1a. The small sample sizes and the absence of data on other host factors that predict the response to treatment, such as IL28B gene polymorphisms (18), precluded statistical analyses of factors determining the response.

A 3-day PegIFN/RBV lead-in period was included before the first dose of faldaprevir, reflecting mainstream treatment strategies at the time of trial onset. Following the commencement of this study, the phase 2 SILEN-C1 and -C2 studies reported that a strategy with no lead-in achieved SVR rates approximately 10% higher than those of lead-in regimens employing otherwise identical doses and durations (14,19), although the reasons for these differences are unknown. Lead-in has not been incorporated into any phase 3 trial design for faldaprevir. This trial demonstrated the efficacy of the 120-mg dose of faldaprevir which has been used to inform phase 3 clinical trials whose results indicate that faldaprevir at 120 mg QD plus PegIFN/RBV without lead-in achieves SVR rates of 79% in treatment-naive patients (20).

Relapse and breakthrough rates for the 12- and 24-week groups were low and consistent with those observed for the same faldaprevir dose in SILEN-C1 (14). The predominance of the major NS3/4A resistance variant R155K in GT-1a and D168V in GT-1b has been observed in earlier studies, and these variants reduce the activity of faldaprevir in vitro (21); this resistance profile overlaps with that of other protease inhibitors (22).

The types and frequencies of AEs were similar in the 12- and 24-week groups. As shown in Table 4, the most common AE was nausea, which occurred in 17% (22%) of patients in the 12-week (24-week) group. Other common AEs included skin disorders (pruritus, dry skin, rash) and gastrointestinal disorders (nausea, vomiting).

RNA result. This indicates that the lower response rates in the 12-week group compared with the 24-week group were due to an imbalance in baseline factors, including age, viral load of ≥800,000 IU/ml, and the proportion of patients who had HCV GT-1a. The small sample sizes and the absence of data on other host factors that predict the response to treatment, such as IL28B gene polymorphisms (18), precluded statistical analyses of factors determining the response.

A 3-day PegIFN/RBV lead-in period was included before the first dose of faldaprevir, reflecting mainstream treatment strategies at the time of trial onset. Following the commencement of this study, the phase 2 SILEN-C1 and -C2 studies reported that a strategy with no lead-in achieved SVR rates approximately 10% higher than those of lead-in regimens employing otherwise identical doses and durations (14,19), although the reasons for these differences are unknown. Lead-in has not been incorporated into any phase 3 trial design for faldaprevir. This trial demonstrated the efficacy of the 120-mg dose of faldaprevir which has been used to inform phase 3 clinical trials whose results indicate that faldaprevir at 120 mg QD plus PegIFN/RBV without lead-in achieves SVR rates of 79% in treatment-naive patients (20).

Relapse and breakthrough rates for the 12- and 24-week groups were low and consistent with those observed for the same faldaprevir dose in SILEN-C1 (14). The predominance of the major NS3/4A resistance variant R155K in GT-1a and D168V in GT-1b has been observed in earlier studies, and these variants reduce the activity of faldaprevir in vitro (21); this resistance profile overlaps with that of other protease inhibitors (22).

The types and frequencies of AEs were similar in the 12- and 24-week groups. As shown in Table 4, the most common AE was nausea, which occurred in 17% (22%) of patients in the 12-week (24-week) group. Other common AEs included skin disorders (pruritus, dry skin, rash) and gastrointestinal disorders (nausea, vomiting).

RNA result. This indicates that the lower response rates in the 12-week group compared with the 24-week group were due to an imbalance in baseline factors, including age, viral load of ≥800,000 IU/ml, and the proportion of patients who had HCV GT-1a. The small sample sizes and the absence of data on other host factors that predict the response to treatment, such as IL28B gene polymorphisms (18), precluded statistical analyses of factors determining the response.

A 3-day PegIFN/RBV lead-in period was included before the first dose of faldaprevir, reflecting mainstream treatment strategies at the time of trial onset. Following the commencement of this study, the phase 2 SILEN-C1 and -C2 studies reported that a strategy with no lead-in achieved SVR rates approximately 10% higher than those of lead-in regimens employing otherwise identical doses and durations (14,19), although the reasons for these differences are unknown. Lead-in has not been incorporated into any phase 3 trial design for faldaprevir. This trial demonstrated the efficacy of the 120-mg dose of faldaprevir which has been used to inform phase 3 clinical trials whose results indicate that faldaprevir at 120 mg QD plus PegIFN/RBV without lead-in achieves SVR rates of 79% in treatment-naive patients (20).

Relapse and breakthrough rates for the 12- and 24-week groups were low and consistent with those observed for the same faldaprevir dose in SILEN-C1 (14). The predominance of the major NS3/4A resistance variant R155K in GT-1a and D168V in GT-1b has been observed in earlier studies, and these variants reduce the activity of faldaprevir in vitro (21); this resistance profile overlaps with that of other protease inhibitors (22).

The types and frequencies of AEs were similar in the 12- and 24-week groups. As shown in Table 4, the most common AE was nausea, which occurred in 17% (22%) of patients in the 12-week (24-week) group. Other common AEs included skin disorders (pruritus, dry skin, rash) and gastrointestinal disorders (nausea, vomiting).

RNA result. This indicates that the lower response rates in the 12-week group compared with the 24-week group were due to an imbalance in baseline factors, including age, viral load of ≥800,000 IU/ml, and the proportion of patients who had HCV GT-1a. The small sample sizes and the absence of data on other host factors that predict the response to treatment, such as IL28B gene polymorphisms (18), precluded statistical analyses of factors determining the response.

A 3-day PegIFN/RBV lead-in period was included before the first dose of faldaprevir, reflecting mainstream treatment strategies at the time of trial onset. Following the commencement of this study, the phase 2 SILEN-C1 and -C2 studies reported that a strategy with no lead-in achieved SVR rates approximately 10% higher than those of lead-in regimens employing otherwise identical doses and durations (14,19), although the reasons for these differences are unknown. Lead-in has not been incorporated into any phase 3 trial design for faldaprevir. This trial demonstrated the efficacy of the 120-mg dose of faldaprevir which has been used to inform phase 3 clinical trials whose results indicate that faldaprevir at 120 mg QD plus PegIFN/RBV without lead-in achieves SVR rates of 79% in treatment-naive patients (20).

Relapse and breakthrough rates for the 12- and 24-week groups were low and consistent with those observed for the same faldaprevir dose in SILEN-C1 (14). The predominance of the major NS3/4A resistance variant R155K in GT-1a and D168V in GT-1b has been observed in earlier studies, and these variants reduce the activity of faldaprevir in vitro (21); this resistance profile overlaps with that of other protease inhibitors (22).

The types and frequencies of AEs were similar in the 12- and 24-week groups. As shown in Table 4, the most common AE was nausea, which occurred in 17% (22%) of patients in the 12-week (24-week) group. Other common AEs included skin disorders (pruritus, dry skin, rash) and gastrointestinal disorders (nausea, vomiting).
24-week groups despite the longer treatment with faldaprevir and PegIFN/RBV in the latter group. This may be because most AEs occurred in the first 12 weeks of therapy and/or because PegIFN/RBV contributed to the AEs (23). Safety and tolerability during faldaprevir treatment were consistent with SILEN-C1 (14) results, and no additional safety concerns were identified. Rash was reported at expected levels (22 to 23%), and only two patients discontinued treatment due to rash. Jaundice, caused by increases in unconjugated bilirubin, was generally mild, uncommon (4 to 5% of patients), and did not lead to treatment discontinuation. Faldaprevir inhibits UGT1A1 (the bilirubin-conjugating enzyme) and, to a lesser extent, the OATP1B1 and MRP2 transporters (24), similar to the HIV protease inhibitor atazanavir, which also causes transient benign elevations in unconjugated bilirubin, regarded as a cosmetic problem rather than a toxicity (25).

Although no direct comparison was made, the incidences of anemia and drug discontinuations due to AEs observed with faldaprevir were lower than those that have been observed in studies with telaprevir and boceprevir (5, 6). This suggests that faldaprevir at 120 mg QD plus PegIFN/RBV enables more treatment-naïve patients with HCV GT-1 to receive a 24-week course of treatment. Simeprevir QD has also achieved increased SVR rates compared to those of PegIFN/RBV treatment alone (26). Unlike faldaprevir, simeprevir does not inhibit UGT1A1 but inhibits OATPs and MRP2 (27), causing increases in conjugated and unconjugated bilirubin.

Major limitations of the current study include the open-label design, the absence of a PegIFN/RBV control arm, and the lack of IL28B testing. Due to the open-label design, safety and tolerability comparisons should be made with caution, but the efficacy end-points are objective and should not be affected by the unblinded treatment duration. Within the phase 2 program for faldaprevir, SILEN-C3 was designed to investigate the efficacy and safety of response-guided faldaprevir at 120 mg for 12 weeks versus 24 weeks, while the randomized, double-blind SILEN-C1 study compared faldaprevir plus PegIFN/RBV treatment to PegIFN/RBV alone (14). At the time of initiation of SILEN-C3, the impact of IL28B genotype on response was not known.

SILEN-C3 showed that addition of faldaprevir at 120 mg QD to PegIFN/RBV enables more treatment-naïve HCV GT-1 patients to receive a total of 24 weeks of therapy, achieves high SVR rates, and is well tolerated. These results support the use of the 120-mg daily dose of faldaprevir currently being investigated in phase 3 clinical trials.

ACKNOWLEDGMENTS

The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development, and have approved the final version.

Medical writing and editorial assistance, supported by Boehringer Ingelheim, was provided by Gail Rickard and Richard Murphy of Adelphi Communications Ltd. and Helen Farrington of Choice Healthcare Solutions Ltd. during the preparation of the manuscript.

REFERENCES

1. Afdhal NH. 2004. The natural history of hepatitis C. Semin. Liver Dis. 24(Suppl 2):3–8. http://dx.doi.org/10.1055/s-2004-832922.
2. Thompson CJ, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, Jackson S, Ryder S, Price A, Stein K. 2007. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol. Assess. 11:1–206.
3. Merck Sharp and Dohme Corp. 2013. Victrelis (boceprevir) prescribing information. Merck Sharp and Dohme Corp., Whitehouse Station, NJ.
4. Vertex Pharmaceuticals Incorporated. 2013. Incivek (telaprevir) highlights of US prescribing information. Vertex Pharmaceuticals Incorporated, Cambridge, MA.
5. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Eliai R, George J, Rizzato M, Shouval D, Dula R, Terg RA, Yoshida EM, Adda N, Bengtsson I, Sankoh AJ, Kieffer TL, George J, Kauffman RS, Zeuzem S, ADVANCE Study Team. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405–2416. http://dx.doi.org/10.1056/NEJMoai1012912.
6. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Bhopari N, Dinhëlle M, Sniukiene V, Brass CA, Albrecht JC, Bronowicki J-P, SPRINT-2 Investigators. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1195–1206. http://dx.doi.org/10.1056/NEJMoai1010494.
7. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F, ILLUMINATE Study Team. 2011. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 365:1014–1024. http://dx.doi.org/10.1056/NEJMoai1114463.
8. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulam F, Canva V, de Ledinghen V, Poycard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric I, Marcellin P, Rischel G, Bernard PH, Loustaud-Ratti V, Métilvier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martin U, Guideray D, Lucidiarne D, Grandjean-Lemaire V, Illion P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP, CUPIC Study Group. 2013. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre co-host of the French Early Access Programme (ANRS CO02-CUPIC)-NCT01514890. J. Hepatol. 59:434–441. http://dx.doi.org/10.1016/j.jhep.2013.04.035.
9. Martel-LaFerrière V, Bichoupan K, Pappas A, Schönfeld E, Ng M, Sefcik R, Vachon M-L, Stendal M, Perumalswami P, Schiano TD, Odin JA, Liu L, Dieterich DT, Branch AD. 2012. Effectiveness of HCV triple therapy with telaprevir in New York city. J. Hepatol. 56(Suppl 2):S344. http://dx.doi.org/10.1001/jhep.2012.50168-82781261150-7.

---

### TABLE 5 Incidence of marked laboratory changes during 12 or 24 weeks of treatment with faldaprevir plus pegylated interferon α-2a and ribavirin

| Laboratory parameter | Value (no [%]) by faldaprevir treatment duration | 12 wk (n = 81) | 24 wk (n = 79) |
|----------------------|-------------------------------------------------|---------------|---------------|
| Total bilirubin      |                                                 | 79            | 78            |
| 1.1–1.5× ULN         | 25 (31.6)                                       | 22 (28.2)     |
| 1.6–2.5× ULN         | 18 (22.8)                                       | 24 (30.8)     |
| 2.6–5.0× ULN         | 6 (7.6)                                         | 6 (7.7)       |
| >5.0× ULN            | 0                                               | 2* (2.6)      |
| ALT                  |                                                 | 79            | 78            |
| 1.25–2.5× ULN        | 37 (46.8)                                       | 38 (48.7)     |
| 2.6–5.0× ULN         | 15 (19.0)                                       | 17 (21.8)     |
| 5.1–10.0× ULN        | 3 (3.8)                                         | 4 (5.1)       |
| >10.0× ULN           | 0                                               | 0             |
| Hemoglobin           |                                                 | 80            | 78            |
| 10.0–10.9 g/dl       | 18 (22.5)                                       | 16 (20.5)     |
| 9.0–9.9 g/dl         | 13 (16.3)                                       | 10 (12.8)     |
| 7.0–8.9 g/dl         | 3 (3.8)                                         | 4 (5.1)       |
| <7.0 g/dl            | 0                                               | 0             |

a Standard reference ranges are the following: total bilirubin, 0.1 to 1 mg/dl; ALT, 0 to 35 U/liter; hemoglobin, 12.5 to 18 g/dl.

b Both patients had a conjugated/total bilirubin ratio of ≤0.5 and total bilirubin levels of 5.2× ULN and 6.6× ULN when the elevation occurred.
10. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Singh HI, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. HCV RESPOND-2 Investigators. 2011. Beceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1207–1217. http://dx.doi.org/10.1056/NEJMoa1009482.

11. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Pinchon O, Bombard C, REALIZE Study Team. 2011. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364:2417–2428. http://dx.doi.org/10.1056/NEJMoa1013086.

12. Asselah T, Marcellin P. 2012. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 32(Suppl 1): 88–102. http://dx.doi.org/10.1111/j.1478-3231.2011.02699.x.

13. Manns MP, Bourlière M, Benhamou Y, Pol S, Bonacini M, Trepo C, Wright D, Berg T, Calleja JL, White PW, Stern JO, Steinmann G, Yong CL, Kukolj G, Scherer J, Böcher WO. 2011. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J. Hepatol. 54:1114–1122. http://dx.doi.org/10.1002/hep.23078.

14. Sulkowski MS, Asselah T, Lalzar I, Ferenci P, Fainboim H, Berenger J, Scher J, Nehmiz G, Steinmann GG, Böcher WO. 2011. Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype-1 HCV: SILEN-C1 trial. Hepatology 57:2143–2154. http://dx.doi.org/10.1002/hep.24276.

15. Kwo PY, Lawitz EJ, McConne P, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhram N, Rossaro L, Anderson FH, Jacobson JM, Rubim R, Koury K, Pecinone LD, Brass CA, Chaudhri E, Albrecht JK, SPRINT-1 Investigators. 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376:705–716. http://dx.doi.org/10.1016/S0140-6736(10)60934-8.

16. Reference deleted.

17. Poordad FF. 2010. Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C. Aliment. Pharmacol. Th. 31:1251–1267. http://dx.doi.org/10.1111/j.1365-2036.2010.04300.x.

18. Estrabaud E, Vidaud M, Marcellin P, Asselah T. 2012. Genomics and HCV infection: progression of fibrosis and treatment response. J. Hepatol. 57:1110–1125. http://dx.doi.org/10.1002/hep.25016.

19. Sulkowski MS, Bourlière M, Bronowicki JP, Asselah T, Pavlotsky JM, Shafran SD, Pol S, Mauss S, Larrey D, Datsenko Y, Stern JO, Kukolj G, Scher J, Nehmiz G, Steinmann GG, Böcher WO. 2013. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 57: 2155–2163. http://dx.doi.org/10.1002/hep.26386.

20. Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, Ouzan D, Maevskaya M, Calinas F, Morano L, Crespo J, Dufour J-F, Bourlière M, Agarwal K, Horton D, Schuchmann M, Zehunter E, Nishi-guchi S, Onnata M, Stern JO, Datzenko Y, Scherer J, Quinson A-M. 2013. Faldaprevir plus pegylated interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-naïve patients: final results from STARTVerso1, a randomised, double-blind, placebo-controlled phase III trial. J. Hepatol. 58(Suppl 1):S569–S570. http://dx.doi.org/10.1016/S0168-2496(13)61415-4.

21. Lagacé L, White PW, Bousquet C, Dansereau N, Dö F, Llinas-Brunet M, Marquis M, Massariol MJ, Maurice R, Spickler C, Thibeault D, Tríki I, Zhao S, Kukolj G. 2012. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob. Agents Chemother. 56:569–572. http://dx.doi.org/10.1128/AAC.05166-11.

22. Berger K, Betheli R, Cartier M, Marquis M, Tríki I, Böcher WO, Datsenko Y, Steinmann GG, Scher J, Stern JO, Kukolj G. 2012. Analysis of baseline polymorphisms and persistence of emergent variants from phase Ib and II trials evaluating the HCV NS3 protease inhibitor BI 201335. Hepatology 56(Suppl 1):785.

23. McClutchison JG, Lawitz EJ, Shiffman ML, Mui A, Galler GW, Mccone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pecinone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 361:580–593. http://dx.doi.org/10.1056/NEJMoa080810.

24. Sane R, Podila L, Mathur A, Mease K, Taub M, Huang Q, Elgadi M, Nehmiz G, Steinmann G. 2011. Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335. J. Hepatol. 54(Suppl 1):S511–S516. http://dx.doi.org/10.1016/S0168-2496(11)61026-9.

25. Sulkowski MS. 2003. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin. Liver. Dis. 23:183–194. http://dx.doi.org/10.1055/s-2003-39499.

26. Fried MW, Buti M, Gore D, Fliksig F, Ferenci P, Jacobson I, Marcellin P, Manns M, Nankin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beaumont-Mauvel M. 2013. Once-daily simprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 58:1918–1929. http://dx.doi.org/10.1002/hep.26641.

27. Hüsiens M, Snoeys J, Monbaliu J, Martens M, Sekar V, Raasof A. 2010. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Hepatology 52(Suppl 1):278.